TORONTO and HOUSTON, Dec. 5, 2018 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna"or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today that it has received US$1,224,540 (approximately, CD$1.6M) from the Cancer Prevention and Research Institute of
The funds received represent a partial reimbursement for eligible expenditures incurred by Medicenna related to the MDNA55 Phase 2b clinical trial for the treatment of recurrent glioblastoma, the most common and uniformly fatal form of brain cancer.
About MedicennaMedicenna is a clinical stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs) for the treatment of a broad range of cancers. Medicenna's wholly owned subsidiary, Houston-based Medicenna BioPharma, is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Supported by a significant non-dilutive grant from CPRIT, Medicenna's lead IL4-EC, MDNA55 is enrolling patients in a Phase 2b clinical trial for recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer, at top-ranked brain cancer centres in the US. MDNA55 has completed three clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA respectively. For more information, please visit www.medicenna.com.
View original content:http://www.prnewswire.com/news-releases/medicenna-receives-us1-2-million-non-dilutive-grant-payment-300760872.html
SOURCE Medicenna Therapeutics Corp.
Subscribe to our Free Newsletters!